TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TKA within 48 hours and VAS\>60 during active 45 degrees knee flexion despite conventional pain medication.~* Informed consent~* ASA 1-3~* BMI 18-40~Exclusion Criteria:~* Unable to communicate in Danish~* Allergic reactions toward drugs used in the~* Abuse of alcohol/drugs~* Unable to cooperate

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Arm RP (Type: OTHER): first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
- Arm PR (Type: OTHER): first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Under a physician's care for CKD for \> 2 months and are not expected to begin dialysis for 4 months~* Screening estimated GFR of 15-59 mL/1.73 m2~* Serum phosphorus \>= 4.7 mg/d following washout~Exclusion Criteria:~* Requiring treatment with cinacalcet HCI or compounds containing phosphate, aluminum, calcium or magnesium~* Rapidly progressing glomerulonephritis~* Cirrhosis or other clinically significant liver diseases~* Past or present uncontrolled peptic ulcer, Crohn's disease, malignancy or recent GI bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged between 5 to 65 years (both inclusive).~* Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration and splenomegaly)~* Presence of amastigotes (Leishmania-Donovani bodies) at prescreening detected by rK39 dipstick test with confirmation by splenic or bone marrow aspirate smear examination.~* Non-pregnant, non-lactating females of age ≥5 years, and woman of childbearing potential who are willing to use acceptable methods of contraception~* Negative Urine pregnancy test (UPT) in all women~Exclusion Criteria:~* Patients with past history of treatment with Amphotericin B or any other drug for Visceral Leishmaniasis within 30 days prior to screening.~* Patients positive for HIV, HCV and HBsAg infection, immunocompromised patients (through history).~* Concurrent diabetes, tuberculosis or bacterial pneumonia or any other infectious or major psychiatric disease.~* Pregnant or nursing women~* Patients receiving any of the medications prohibited by the study protocol.~* Simultaneous participation in another trial or received any IP \<30 days prior to enrolment.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amphotericin B lipid emulsion (Type: EXPERIMENTAL): Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
- Liposomal Amphotericin B (Type: ACTIVE_COMPARATOR): Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Paroxysmal, persistent or permanent non-valvular AF~* Eligible for long-term warfarin therapy~* Eligible to come off warfarin therapy~* Calculated CHADS2 score of 2 or greater. Also patients with a CHADS2 score of 1 may be included if any of the following apply:~  * Female age 75 or older~ * Baseline LVEF ≥ 30 and \< 35%~ * Aged 65-74 and has diabetes or coronary artery disease~ * Aged 65 or greater and has congestive heart failure~Key Exclusion Criteria:~* Contraindicated/allergic to aspirin~* Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment~* History of atrial septal repair or has an ASD/PFO device~* Implanted mechanical valve prosthesis~* NYHA Class IV CHF~* Resting heart rate \> 110 bpm~* Participated previously in the PROTECT AF or CAP Registry studies~Key Echo Exclusion Criteria:~* LVEF \< 30%~* Existing pericardial effusion \> 2mm~* High risk PFO~* Significant mitral valve stenosis~* Complex atheroma with mobile plaque of the descending aorta and/or aortic arch~* Cardiac tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WATCHMAN (Type: EXPERIMENTAL): Subjects assigned to receive the WATCHMAN device.
- Warfarin (Type: ACTIVE_COMPARATOR): Subjects assigned to warfarin therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study In Adults And Adolescents With Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Informed consent.~* Outpatient.~* Females must use appropriate contraception.~* Diagnosis of seasonal allergic rhinitis.~* Adequate exposure to allergen.~* Able to comply with study procedures.~* Literate.~Exclusion criteria:~* Significant concomitant medical condition.~* Use of corticosteroids, allergy medications, or tobacco.~* Clinically significant abnormal ECG.~* Laboratory abnormality.~* Positive pregnancy test.~* Allergy to any component of the investigational product.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* History of asthma for at least 6 months~* Ability to show optimal use of MDI, including inhalation technique~* Lung function and reversibility within specified limits~Main Exclusion Criteria:~* Concomitant severe diseases~* Diseases which are contraindications for the use of inhaled steroids~* Two or more inpatient hospitalizations for asthma within the last year~* Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study~* Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6 weeks)~* Beginning of or change in immunotherapy within the last 6 months prior to inclusion~* Inability to follow the procedures of the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Ciclesonide 40 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Ciclesonide 80 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Ciclesonide 160 µg (Type: ACTIVE_COMPARATOR): Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Before screening, subjects (or legally authorized representative) must read and sign the IRB approved Informed Consent Form (includes HIPPA and Photo release)~* Subjects must have Fitzpatrick Skin Type I, II or III, and judged by the Investigator to have healthy skin~* Subject's bilateral facial skin must be clear of any confounding irritation, rashes, acne, rosacea, etc. prior to the study~* Subject must be free of systemic retinoids for at least 2 months~* Subject must not be using any topical retinoids, systemic antibiotics, nicotinamide or systemic steroids for 1 month prior to study start~* All other topical medications to face (e.g., steroids, antimicrobials, salicylic acid and benzoyl peroxide) and cosmetics containing retinols, AHA's and bleaching agents such as hydroquinone are to be discontinued at least 2 weeks prior to study initiation~* Subjects will not apply any emollients and cosmetics to the facial area 24 hours prior to study initiation~* Subject must not be planning to become pregnant or nursing before entering the study and during the study period. In addition if using birth control pills, subject must be stabilized for at least 2 months. If subject is of child bearing potential, subject must be using approved method of birth control. Approved methods are birth control pills, implants, patches or spermicide with condoms.~Exclusion Criteria:~* Subjects who are pregnant or nursing~* Subjects who have a grade 1 or more for facial erythema~* Subjects who exhibit any skin condition (i.e., atopic dermatitis, seborrheic dermatitis, and psoriasis) or disease that may require concurrent therapy or may confound the evaluation of drug safety or efficacy~* Subjects who have a history of hypersensitivity to any of the formulation components listed in Appendix 1.~* Subjects who have received any experimental drug or used any experimental device 30 days prior to initiation of study therapy~* Subjects who have excessive facial hair that may obstruct or hinder the evaluation of any reactions~* Subjects who use any known photosensitizing agents~* Subjects who presently have skin cancer or actinic keratosis on the face

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Two interventions in split-face model (Type: EXPERIMENTAL): Once daily use in a split face model:~1. Tretinoin gel~2. Adapalene Benzoyl peroxide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease undergoing maintenance hemodialysis at KUMC outpatient hemodialysis unit~* Dialysis vintage of at least 6 months duration~* Nutritional vitamin D deficiency, defined as 25(OH)D \<25 ng/ml~* Age 21 to 88 years~Exclusion Criteria:~* Active infection~* Recent hospitalization for acute illness (within last 1 month)~* Refusal to study participation~* Poorly controlled secondary hyperparathyroidism (iPTH\>500)~* History of chronic inflammatory disease process, such as inflammatory bowel, rheumatoid arthritis, lupus, etc.~* Cinacalcet therapy~* Previous allergy to ergocalciferol~* History of parathyroidectomy~* Current treatment with immunosuppressant medications~* Noncompliance with prescribed hemodialysis regimen (i.e. skipping treatments, ending sessions early)~* Functional renal transplant within the last five years

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cholecalciferol (Vitamin D)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1~Exclusion Criteria:~* Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Healthy male subjects

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 10773 25 mg (Type: EXPERIMENTAL): 1 tablet 25 mg BI 10773 qd for 5 days
- BI 10773 25 mg + Warfarin 25 mg (Type: EXPERIMENTAL): 1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
- Warfarin 25 mg (Type: ACTIVE_COMPARATOR): 5 tablets 5 mg warfarin single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older with an overall baseline Lip Fullness Scale (LFS) score of minimal, mild or moderate on the 5-point LFS scale.~* Has the ability to follow study instructions and is likely to complete all required visits~Exclusion Criteria:~* Has had any facial procedures or trauma that may interfere with the study procedures and results~* Is on anti-coagulation therapy or other contraindicated treatments~* Has current cutaneous inflammatory or infectious processes or lesions in the mouth area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- JUVÉDERM® VOLBELLA® XC with Lidocaine (Type: EXPERIMENTAL): JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
- No-treatment Control (Type: EXPERIMENTAL): No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of PLX108-01 in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older~* Solid tumors refractory to standard therapy~* For the Extension cohorts, patients must have measurable disease by RECIST criteria and meet the following disease-specific criteria:~  * For advanced or recurrent mucoepidermal carcinoma (MEC) of the salivary gland, patients must not be candidates for curative surgery or radiotherapy.~ * For pigmented villo-nodular synovitis (PVNS), patients must have a histologically confirmed diagnosis of inoperable progressive or relapsing PVNS, or resectable tumor requesting mutilating surgery, as well as demonstrated progressive disease in the last 12 months.~ * For gastrointestinal stromal tumors (GIST), patients must have failed previous therapy with imatinib and sunitinib. Patients with known PDGFR mutations are excluded, but mutation testing is not required for study entry.~ * For anaplastic thyroid cancer (ATC), patients must have histologically or cytologically diagnosed advanced ATC.~ * For metastatic solid tumors with documented malignant pleural and/or peritoneal effusions, patients must not be receiving specific therapy for the effusion or have an indwelling drain.~* Eastern Cooperative Oncology Group performance status 0 or 1~* Life expectancy \>= 3 months~* Adequate hepatic, renal, and bone marrow function~Exclusion Criteria:~* Specific anti-cancer therapy within 3 weeks of study start~* Uncontrolled intercurrent illness~* Refractory nausea or vomiting, or malabsorption~* Mean corrected QT interval (QTc) \>= 450 msec (for males) or QTc \>= 470 msec (for females)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLX3397 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the time of screening as established in the medical history.~* Patients aged 20 to 75 years at screening.~* Body mass index ≤35 kg/m\^2 at screening.~* Glycohemoglobin ≥7.0% and ≤10.0% at screening.~* Fasting C-peptide ≥0.6 ng/mL at screening.~Exclusion criteria:~* Diabetes other than T2DM.~* History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening.~* History of hypoglycemia unawareness.~* Hemoglobinopathy or hemolytic anemia.~* History of myocardial infarction, stroke, or heart failure, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.~* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment.~* Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).~* If female, pregnancy or breast-feeding.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine/ lixisenatide dose 1 Test 1 (Type: EXPERIMENTAL): Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Insulin glargine/ lixisenatide dose 2 Test 2 (Type: EXPERIMENTAL): Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Placebo - Reference 1 (Type: PLACEBO_COMPARATOR): Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Insulin glargine (Lantus) - Reference 2 (Type: OTHER): Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete